Related references
Note: Only part of the references are listed.Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2014)
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents - Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay et al.
EUROPEAN JOURNAL OF CANCER (2014)
Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4
Jyothsna Gattineni et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
Fabrice Andre et al.
CANCER RESEARCH (2013)
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci et al.
CANCER DISCOVERY (2013)
CXCR4 Activation Defines a New Subgroup of Sonic Hedgehog-Driven Medulloblastoma
Rajarshi Sengupta et al.
CANCER RESEARCH (2012)
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
A. Nigel Brooks et al.
CLINICAL CANCER RESEARCH (2012)
Fibroblast growth factors and their receptors in cancer
Jorgen Wesche et al.
BIOCHEMICAL JOURNAL (2011)
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
Ezia Bello et al.
CANCER RESEARCH (2011)
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Christopher Lieu et al.
CLINICAL CANCER RESEARCH (2011)
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
Federica Sala et al.
JOURNAL OF MASS SPECTROMETRY (2011)
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Amit Dutt et al.
PLOS ONE (2011)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
FGFR1 and FGF Coamplification in Breast Cancer.
L. Albiges et al.
CANCER RESEARCH (2010)
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas Turner et al.
CANCER RESEARCH (2010)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
N. Turner et al.
ONCOGENE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Axel Grothey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
Somaia Elbauomy Elsheikh et al.
BREAST CANCER RESEARCH (2007)
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
Jorge Sergio Reis-Filho et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
